Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $9.6 million.

  • GeneDx Holdings' Free Cash Flow rose 28409.44% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 12599.28%. This contributed to the annual value of -$34.0 million for FY2024, which is 8166.8% up from last year.
  • As of Q3 2025, GeneDx Holdings' Free Cash Flow stood at $9.6 million, which was up 28409.44% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Free Cash Flow ranged from a high of $9.6 million in Q3 2025 and a low of -$90.4 million during Q3 2022
  • Over the past 5 years, GeneDx Holdings' median Free Cash Flow value was -$41.3 million (recorded in 2023), while the average stood at -$38.2 million.
  • As far as peak fluctuations go, GeneDx Holdings' Free Cash Flow crashed by 2000180.2% in 2021, and later surged by 28409.44% in 2025.
  • GeneDx Holdings' Free Cash Flow (Quarter) stood at -$54.6 million in 2021, then decreased by 19.6% to -$65.3 million in 2022, then surged by 50.66% to -$32.2 million in 2023, then soared by 81.19% to -$6.1 million in 2024, then skyrocketed by 258.28% to $9.6 million in 2025.
  • Its Free Cash Flow stands at $9.6 million for Q3 2025, versus $8.1 million for Q2 2025 and $4.1 million for Q1 2025.